HPV Testing for Cervical Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method for screening cervical cancer in the Emergency Department using HPV testing, which detects human papillomavirus, a potential cause of cervical cancer. Participants can collect their own sample during their visit, following simple instructions from the study staff. The trial seeks cisgender women and transgender or non-binary individuals with a cervix, aged 25 to 65, who have not undergone a hysterectomy that removed the cervix. As an unphased trial, it offers participants the chance to contribute to innovative screening methods that could enhance early detection of cervical cancer.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that HPV testing is safe for cervical cancer screening?
Research has shown that HPV testing is a safe and well-tolerated method for cervical cancer screening. Studies have found that undergoing an HPV test every five to eight years after a negative result is as safe as more frequent testing. This approach reduces the risk of developing cervical cancer compared to older methods like microscopic cell examination.
Additionally, HPV testing has led to a significant drop in early signs of cervical cancer. From 2008 to 2022, cases among young women who were screened decreased by 79%. Women who underwent HPV-based screenings had a 28% lower chance of developing serious cervical cancer compared to those using the older cell examination method.
Overall, these findings demonstrate that HPV testing is a safe and effective way to detect cervical cancer early and reduce the risk of serious health issues.12345Why are researchers excited about this trial?
Researchers are excited about the HPV testing method being studied for cervical cancer because it offers a unique approach to early detection. Unlike traditional Pap smears that require clinical sampling, this method allows individuals to self-sample for HPV, increasing accessibility and privacy. This could lead to higher participation rates in screening programs, especially for those who may avoid clinical settings. By enabling more people to conveniently test themselves, this approach has the potential to improve early detection and ultimately reduce cervical cancer rates.
What evidence suggests that HPV testing is effective for cervical cancer screening?
In this trial, participants can self-sample for HPV during their ED visit. A previous study found that testing for HPV (human papillomavirus) is the most effective and affordable method for checking cervical cancer. Research has shown that screening for HPV is more effective at preventing serious cervical cancer than other methods. Between 2008 and 2022, cases of early cervical cancer dropped by 79% among women aged 20 to 24 who were screened. Another study found an 80% decrease in more severe early cervical cancer in the same group. These findings suggest that HPV testing is a strong tool for lowering the risk of cervical cancer.35678
Are You a Good Fit for This Trial?
This trial is for individuals who visit the emergency department and may be at risk of cervical cancer or human papillomavirus (HPV) infection. Specific eligibility criteria are not provided, but typically participants would need to meet certain health conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants are instructed on self-sampling for HPV during their ED visit
Follow-up
Participants receive a follow-up call to assess uptake of cervical cancer screening
What Are the Treatments Tested in This Trial?
Interventions
- HPV Testing
Trial Overview
The study is testing the feasibility and effectiveness of conducting HPV testing as a method for cervical cancer screening in an emergency department setting.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants in this arm will be provided the opportunity to self- sample for HPV during their ED visit. Participants will be (1) briefly instructed by the study staff on how to self-sample using a defined instructional script written at an elementary reading level, (2) provided with a packaged swab and vial of transport media, and (3) invited to self- sample privately in their ED room or in one of the private ED restrooms.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
Citations
Benefits, harms and cost-effectiveness of cervical screening ...
Assuming 70% coverage, we found that primary human papillomavirus (HPV) screening approaches were the most effective and cost-effective, ...
Trends in Cervical Precancers Identified Through ...
During 2008–2022, cervical precancer incidence decreased 79% and higher-grade precancer incidence decreased 80% among screened women aged 20–24 years.
Human papillomavirus-based cervical screening and long- ...
This randomised policy trial found HPV-based screening to be superior for preventing invasive cervical cancer in the real-world setting.
Cervical Cancer Screening, HPV Vaccination, and ...
This decision analytical model study examines how different strategies for Papanicolaou testing, human papillomavirus (HPV) testing, and HPV ...
Primary human papillomavirus testing vs cotesting: clinical ...
These data suggest that cotesting confer an unfavorable benefit-to-harm ratio over primary HPV testing.
Screening for Cervical Cancer - PMC
Testing using HPV assays at 5-year intervals results in a lower risk of cancer and precancer than cytology testing at 3-year intervals. Sequential negative HPV ...
HPV Testing for Cervical Cancer May Be Safe at Longer ...
HPV testing eight years after a negative result instead of the recommended five was found comparable to standard cytology screening.
8.
acsjournals.onlinelibrary.wiley.com
acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21628Cervical cancer screening for individuals at average risk: 2020 ...
The evidence from RCTs and other studies showed that HPV-based cervical cancer screening has superior sensitivity and long-term negative ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.